Tagged with Investment,

India Poised to overtake Japan and become the world’s fourth-largest economy by 2025 according to the latest International Monetary Fund estimates and now registering heady year-on-year growth rates exceeding eight percent, India’s overall business outlook appears increasingly rosy with industry reaping the rewards from rising per capita GDP, enhanced purchasing power,…

Brazil With the largest public healthcare system in the world, Latin America’s biggest pharma market, its leading regulatory body, and a huge and diverse population, Brazil is a strategic destination for both regional and global pharma. Read on for five things to watch in 2024 and beyond from this dynamic nation. …

Saudi Arabia As life expectancy increases, how do we ensure that quality of life does too? That is the conundrum that Saudi Arabia’s Hevolution Foundation was set up to help solve. Hevolution invests in extending the healthy human lifespan across the world through research and treatments which target age-related diseases and conditions.…

Global Brendan Shaw paints a concerning picture of global health priorities post-pandemic, highlighting the need for renewed focus and investment in healthcare systems to prevent further backsliding.   “There isn’t a financing gap. There is just money that is not moving towards the right things. There’s plenty of money out there”…

Saudi Arabia Over the past three years, Sanofi has significantly expanded its presence in the GCC region, launching 40-50 new products, including treatments for rare diseases and advancements in immunology, diabetes management, and vaccines. As Jean-Paul Scheuer explains, this expansion aligns with Sanofi’s goal to become a leading immunology company globally and…

UAE Long-established as the Middle East and Africa’s leading country in terms of rapid access to biomedical innovation, the UAE is looking to bolster this positioning in the coming years. Indeed, allowing innovation to flourish – including through hosting greater numbers of clinical trials in the country and protecting intellectual property…

Hong Kong VMS Group was founded in 2006 and since then has built close relationships with a handful of large anchor investors, including some of the largest families in Hong Kong. Apart from managing over USD 4.3 billion across its three in-house strategies – Private Equity, Real Estate and Structured Finance, it…

China Prof. Song Ruilin outlines the Chinese (bio)pharmaceutical industry’s progress across the three key pillars of innovation, industrialization, and internationalization in recent years. While a downturn in the global economy and a capital freeze in the biotech sector present significant challenges, Song is optimistic about his sector’s prospects, with increased international…

India Regular contributor Brendan Shaw gives his informed take on how best international stakeholders can engage with India’s attempts to transform into a global pharma innovation powerhouse,   Our greatest ability as humans is not to change the world, but to change ourselves Mahatma Gandhi The secret to success in India…

India Dr Viranchi Shah of Saga Lifesciences and the Indian Drug Manufacturers Association (IDMA) outlines the Indian pharmaceutical industry’s potential for growth and its role in global health initiatives. He highlights IDMA’s focus on scaling operations, affordability, accessibility, quality, and compliance to drive positive change across the sector. Dr Shah also…

India Multinational life science firms have been present in India for decades. However, they have often eschewed bringing their latest products to a country that has long prioritised affordability above innovation. Now though, as India’s GDP and market value soar and the policy environment shifts towards prioritising the domestic development of…

Saudi Arabia As the GCC’s largest market, Saudi Arabia, with its growing population, strong healthcare infrastructure and government commitment to developing the economy beyond oil through its Vision 2030, is increasingly attractive for multinational pharma and local players alike. In 2024 government reforms will continue to encourage investment and local production while…